Diabetes Mellitus, Type 2
Conditions
Brief summary
The aim is to continue our program on PDE5 inhibition by evaluating effects on insulin resistance, including glucose metabolism and subclinical inflammation, after a 6-week administration of tadalafil in T2D patients. The primary objective is to study the effect of tadalafil compared with placebo on insulin sensitivity during a euglycemic hyperinsulinemic clamp. This is a double-blind, placebo-controlled crossover study with one study site. Twenty-five T2D patients will be recruited and randomized to per oral intake of tadalafil 20 mg o.d. for six weeks and after a wash-out period of eight weeks intake of placebo for another six weeks, or vice versa. At the end of each 6 week treatment period a glucose clamp, subcutaneous needle biopsies as well as muscle and subcutaneous microdialysis will be performed. Endothelial function tests and arginin stimulation of insulin secretion tests will be performed after 3 weeks in each treatment arm.
Interventions
DRUGTadalafil
DRUGPlacebo
Per oral intake of placebo for six weeks
Sponsors
Vastra Gotaland Region
Göteborg University
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
40 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. T2D patient, previously diagnosed by fasting or 2-hr OGTT plasma glucose levels 2. Age females: 55-70 yrs (post-menopausal state defined as natural amenorrhea for at least 12 months); Age males: 40-70 yrs 3. BMI: 27-40 kg/m2 4. HbA1c \< 60 mmol/mol 5. Type 2 diabetes duration \> 3 months and \< 10 yrs 6. Understand and speak Swedish
Exclusion criteria
1. Diabetes treatment with glitazones, GLP-1 analogues or DPP-IV inhibitors 2. Anti-hypertensive therapy with beta-blockers, ACE-inhibitors and/or angiotensin-II receptor blockers 3. Significant microvascular complications e.g. nephropathy (GFR\<60), proliferative retinopathy and symptomatic neuropathy e.g. postural hypotension 4. Previous significant vascular disease including angina pectoris and myocardial infarction, cerebral artery disease e.g. history of transient ischemic attacks and peripheral artery disease with no palpable pulses 5. Smoking \> 10 cig/day and/or smokeless tobacco \> one can per 2 days 6. Concurrent use of nitrates or NO donors, or an apparent risk that there may be a need of such medication 7. Cardiac failure (stages NYHA II-IV) 8. Uncontrolled hypertension \> 170/105 mm Hg 9. Apparent ECG-pathology indicating current or previous myocardial ischemia; 10. Males with erectile dysfunction 11. Hemophilia or a history of bruises or hepatic failure (\> 2-fold increase upper limit normal values of ASAT/ALAT) 12. Hypotension 13. Treatment with doxazosin 14. Anything in the contact with the patient that makes the doctor to believe that he/she will be uncompliant to the protocol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| insulin sensitivity | 6 week treatment with drug or placebo | To evaluate the effect (difference in glucose disposal rate (mg/kg/min)) of daily administration of 20 mg tadalafil for 6 weeks (chronic treatment) on insulin sensitivity in muscle by assessing glucose disposal rate during a 3-hour euglycemic hyperinsulinemic glucose clamp (120 mU/m2/min) in T2D patients |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Fasting plasma glucose levels (mmol/l) | Up to 6 weeks after start of treatment. | Evaluation the effect of chronic tadalafil treatment on glucose metabolism and beta-cell function as measured by circulating glucose levels |
| Arginine-induced insulin secretion (area under curve, AUC, mU/l/min) in blood | 3 weeks after start of treatment. | Glucose metabolism and beta-cell function as measured by arginine-induced insulin secretion (difference in AUC, mU/l/min). |
| Levels interstitial insulin | Up to 6 weeks after start of treatment. | levels interstitial insulin (mU/l) |
| Mean glucose (HbA1c, mmol/mol) in blood | Up to 6 weeks after start of treatment. | Evaluation the effect of chronic tadalafil treatment on glucose metabolism and beta-cell function as measured by mean blood glucose (HbA1c) |
| Levels of inflammatory markers in blood | Up to 6 weeks after start of treatment. | Difference in endothelin-1 levels (pg/ml) |
| Endothelial function in peripheral arteries measured with EndoPAT, measured as difference in reactive hyperemia | 3 weeks after start of treatment. | — |
| Lactate concentrations in insulin sensitive tissues | Up to 6 weeks after start of treatment. | Lactate concentrations (micromoles/l) in insulin sensitive tissues |
Countries
Sweden
Outcome results
None listed